About Ensol

History

History of Ensol, a leader of innovative new drug discovery

2019

2019.05

Application for license to sell animal osteoarthritis drug (EAD100) (Korea QIA)

2018

2018.12

Phase 1 clinical trial approval for osteoarthritis drug (Engedi1000)

2018.12

Ranked 347th in rapidly growing Asia-Pacific company in ‘Life science’ (biopharmaceutical included) selected by ‘Deloitte’ Global

2018.09

Listed on KONEX (10th)

2018.09

Expanded to CMC CDO for anticancer drug candidate material

2018.07

Technology transfer agreement for degenerative disc disease drug (Peniel2000) (Spine Biopharma, LLC (USA))

2018.06

IND clinical trial application for osteoarthritis drug (Engedi1000)

2018.05

Approval completed for clinical trial plan of animal drug ‘canine osteoarthritis drug (EAD100)’

2017

2017.08

Development of pharmacokinetic mechanism prediction system (ETONS) ver 1.0

2017.03

Discovery of type 1 diabetes drug (Shiloah1000)

2016

2016.08

Launched high-purity phytochemical production/sales, analysis/separation service, peptide and chemical synthesis service

2016.05

Discovered Alzheimer’s disease drug (Moria1000) candidate material

2015

2015.08

Changed company name to Ensol Biosciences Inc.

2015.03

Discovery of anticancer drug candidate (Charis1000)

2014

2014.09

Approval of clinical trial for the degenerative disc disease drug (Peniel2000), Phase2b.

2014.02

Completion of clinical trial for the degenerative disc disease drug (Peniel2000), Phase 1/2a

2013

2013.01

Peniel2000 was published in the Spine online

2012

2012.11

Approval of clinical trial for the degenerative disc disease drug (Peniel2000)

2012.09

Technology Development Project Phase 2 Bio-hydrogen substantiation production agreements (Ministry of Land, Transport and Maritime Affairs)

2011

2011.12

Development of new drug for rheumatoid arthritis treatment

2011.11

Company building construction and moving (51, Techno 10-ro, Yuseong-gu, 34036, Daejeon, Korea)

2011.03

License-out agreement for the joint development of osteoarthritis drug (Peniel 1000) and investment with Yuhan Corp.

2010

2010.07

Development of protein interaction network analysis solution, NAS

2010.04

Development of osteoarthritis drug (Peniel1000)

2009

2009.10

License-out agreement for the joint development of degenerative disc disease (DDD), with Yuhan Corp.

2009.08

Development of degenerative disc disease (DDD) drug called Peniel2000

2009.07

Winning national project for the development of bio-hydrogen production technology from MLTM

2008

2008.11

Development of integrated microbial genome analysis solution, EMFAS

2008.05

Winning national project for the development of marine biodiversity information system project from NFRDA

2008.03

Development of protein functional linkage analysis solution, FLiPS

2007

2007.07

Winning technology innovation R&D project from SMB

2006

2006.08

Winner of ‘RED HERRING ASIA 100’ in 2006

2006.07

Development of protein identification solution, ProteinFinder

2005

2005.05

Development of high-speed parallel processing BLAST, Hyper-BLAST

2005.05

Collaboration agreement with CJ Corp.

2004

2004.04

Protein informatics solution ProteinStar/TargetStar announced

2004.01

Military service’s exemption company approved

2002

2002.07

Selected as INNO-BIZ – Small and Medium Business Administration

2002.03

Joint research agreement with CJ Bio R&D center

2001

2001.12

Winner of IMT-2000 bioinformatics project from MAF (R&D Fund: 3.2 M$)

2001.10

Award for excellent new technology (IT-Mark)

2001.07

‘Certificate of Venture Business’ acquired from SMBA

2001.07

‘Certificate of Company Research Institute’ approved from KOITA

2001.02

Ensoltek Co., Ltd. founded by Hae-Jin Kim (Ph.D., CEO)